MedDataX Logo

Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

NCT ID: NCT07146113

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-30

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicentre observational study on treatment approaches and biomarkers in de novo metastatic hormone sensitive prostate cancer in Russian Federation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicentre observational study on treatment approaches, demographic and clinical characteristics and prevalence of biomarkers (PTEN-loss, HER2-positive status; HRR mutations, HRD-positive status) in patients with de novo high-aggressive mHSPC in Russian Federation. The study will sequentially include only those patients who have signed the informed consent form (ICF). No procedures will be applied to patients in addition to the routine clinical practice.

Study population will consist of patients with de novo high-aggressive (Gleason 8-10) histologically confirmed mPC diagnosed within 2 years prior to inclusion with available medical history, biopsy formalin-fixed paraffin-embedded (FFPE) tumour tissue sample. It is estimated that approximately 400 patients will be enrolled in about 30 sites.

Demographic and clinical characteristics, treatment approaches and outcomes will be collected during a single visit carried out according to routine clinical practice. Data from the date of de novo high-aggressive mPC diagnosis (date of histological verification) till enrollment will be collected by study physician based on the patient's medical records and interview during the visit and entered into electronic case report form (eCRF). The study physician will be responsible for ensuring that all required data is collected and entered into the eCRF. No follow-up is planned for patients in this study.

For PTEN-loss and HER2-hyperexpression testing (by IHC) and HRRm (mutations in HRR pathway genes), HRD testing (by NGS \[next generation sequencing\]) available FFPE tumour tissue sample collected as part of routine clinical practice will be used. Testing will be performed in central laboratories.

Overall expected duration of the study enrollment and data collection (from the first patient inclusion to the final database lock) is about 27 months, or until 400 eligible patients are included to the study and data on these patients are collected (including results of FFPE sample testing), whichever occurs first.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male patients aged ≥ 18 years old;
2. Signed ICF, including consent for FFPE tumor tissue sample testing;
3. De novo histologically confirmed high-aggressive (Gleason 8-10) mPC;
4. Diagnosis of mPC (metastatic prostate cancer) within 2 years prior to inclusion;
5. Availability of source medical documentation;
6. Presence of biopsy FFPE tumor tissue sample, obtained as part of standard clinical practice, which will be used for biomarker testing;
7. Unknown HRRm status.

Exclusion Criteria

1\. Participation in any interventional trial since the mPC diagnosis.
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Arkhangelsk, , Russia

Site Status RECRUITING

Research Site

Barnaul, , Russia

Site Status RECRUITING

Research Site

Chelyabinsk, , Russia

Site Status RECRUITING

Research Site

Irkutsk, , Russia

Site Status NOT_YET_RECRUITING

Research Site

Krasnodar, , Russia

Site Status NOT_YET_RECRUITING

Research Site

Krasnoyarsk, , Russia

Site Status RECRUITING

Research Site

Moscow, , Russia

Site Status NOT_YET_RECRUITING

Research Site

Moscow, , Russia

Site Status RECRUITING

Research Site

Nizhny Novgorod, , Russia

Site Status NOT_YET_RECRUITING

Research Site

Obninsk, , Russia

Site Status RECRUITING

Research Site

Omsk, , Russia

Site Status RECRUITING

Research Site

Saint Petersburg, , Russia

Site Status NOT_YET_RECRUITING

Research Site

Saransk, , Russia

Site Status NOT_YET_RECRUITING

Research Site

Tomsk, , Russia

Site Status NOT_YET_RECRUITING

Research Site

Tyumen, , Russia

Site Status NOT_YET_RECRUITING

Research Site

Ufa, , Russia

Site Status NOT_YET_RECRUITING

Research Site

Yekaterinburg, , Russia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Russia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

AstraZeneca Clinical Study Information Center

Role: CONTACT

Phone: 1-877-240-9479

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D133HR00058

Identifier Type: -

Identifier Source: org_study_id